Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
CD73 Inhibitor
MRS4620 is a potent inhibitor of CD73, exhibiting an inhibitory constant (Ki) of 0.436 nM. This compound is primarily utilized in cancer immunology research, where it can help elucidate the role of CD73 in immune regulation and tumor microenvironment modulation. MRS4620 is valuable for studies aimed at enhancing anti-tumor immunity and understanding the mechanisms of immune evasion in cancer. -
CD73 Inhibitor
CD73-IN-9 is a potent inhibitor of CD73, an enzyme that catalyzes the conversion of extracellular 5'-AMP to adenosine. Elevated adenosine levels are associated with immunosuppressive effects and can promote tumor proliferation and metastasis. This compound is valuable for investigating tumor-related diseases and understanding the role of CD73 in cancer biology. -
OTUD4/CD73 Inhibitor
ST80 is an inhibitor of the OTUD4/CD73 interaction. It effectively decreases the protein level of CD73 and enhances its turnover, which reduces the immune evasion capabilities of tumor cells. This results in significant antitumor efficacy, particularly in the context of immunosuppressive triple-negative breast cancer (TNBC), making ST80 valuable for research in cancer immunotherapy. -
CD73 Inhibitor
PSB-0963 is a selective and competitive inhibitor of ecto-5'-nucleotidase (eN or CD73), exhibiting an inhibition constant (Ki) of 150 nM for rat ecto-5'-nucleotidase. This compound demonstrates high selectivity for eN/CD73 over other ectonucleotidases, such as NTPDases 1-3, and P2Y receptors. PSB-0963 is valuable for research involving cancer biology, particularly in studies focused on immune regulation and tumor microenvironment interactions. -
CD73 Inhibitor
CD73-IN-12 is a potent inhibitor of CD73, an enzyme implicated in tumor growth, angiogenesis, and metastasis. This compound serves as a valuable tool for investigating tumor-related diseases and their underlying mechanisms. Additionally, CD73-IN-12 features an alkyne group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), making it useful for click chemistry applications in biochemical research. -
CD73 Inhibitor
CD73-IN-18 is a potent inhibitor of extracellular 5-nucleotidase (CD73). By blocking CD73 activity, this compound has shown potential in anti-cancer research, enhancing immune responses against tumors. It serves as a valuable tool in studies aimed at understanding tumor microenvironments and developing novel cancer therapies. -
CD73 Inhibitor
CD73-IN-6 is a potent inhibitor of CD73, a key enzyme involved in the adenosine pathway. This compound is essential for investigating the role of CD73 in cancer biology and its potential therapeutic applications. CD73-IN-6 can be utilized in research focused on tumor immunology and the modulation of the tumor microenvironment, providing insights into cancer progression and treatment strategies. -
CD73 Inhibitor
CD73-IN-7 is a potent inhibitor of CD73, an enzyme that catalyzes the conversion of extracellular 5'-AMP to adenosine. Adenosine plays a critical role in immunosuppression and can facilitate tumor proliferation and metastasis. CD73-IN-7 is suitable for research applications focused on tumor biology and the modulation of immune responses in cancer. -
CD73 Inhibitor
MethADP disodium is a specific inhibitor of CD73, an enzyme involved in the regulation of adenosine signaling. By inhibiting CD73 activity, MethADP disodium can impede the production of adenosine, which plays a critical role in immune suppression and tumor progression. This compound is useful for research applications focusing on cancer immunotherapy, inflammation, and metabolic diseases, providing insights into the modulation of the adenosine pathway. -
COX Inhibitor
Inulicin (1-O-Acetylbritannilactone) is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically targeting COX-2 activity. This compound demonstrates significant biological activity by inhibiting lipopolysaccharide (LPS)-induced production of prostaglandin E2 (PGE2) as well as the expression of COX-2. Additionally, Inulicin suppresses NF-κB activation and its translocation, making it valuable for research applications related to inflammation and cancer. -
COX Inhibitor
COX-1-IN-3 is a selective inhibitor of cyclooxygenase-1 (COX-1), exhibiting non-steroidal anti-inflammatory properties. This compound is valuable for research focused on inflammation and pain management, as it modulates the biosynthesis of prostaglandins. Its specificity for COX-1 makes it an important tool for studying COX-1-related pathways and associated biological processes. -
COX Inhibitor
(S)-Ketorolac is a nonsteroidal anti-inflammatory drug that primarily functions as an inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes. This compound is characterized by its potent analgesic and anti-inflammatory properties, making it suitable for pain management in various research applications. Its ability to selectively inhibit COX enzymes positions (S)-Ketorolac as a valuable tool in studies focused on inflammatory processes and pain modulation. -
COX Inhibitor
(±)-Naproxen is a non-steroidal anti-inflammatory drug that inhibits both COX-1 and COX-2 enzymes, exhibiting IC50 values of 8.72 μM and 5.15 μM, respectively. This compound is primarily used in research for its potent anti-inflammatory and analgesic properties. It provides valuable insights into the mechanisms of pain relief and inflammation, making it suitable for various studies in pharmacology and biochemistry. -
sEH/COX-1 Inhibitor
PTUPB is a potent dual inhibitor of soluble epoxide hydrolase (sEH) and cyclooxygenase-1 (COX-1), exhibiting IC50 values of 0.9 nM and 1.26 μM, respectively. This compound is relevant for studies investigating the modulation of inflammatory processes, as it effectively interferes with pathways involving arachidonic acid metabolism. PTUPB serves as a valuable research tool for exploring the therapeutic potential of sEH and COX-1 inhibition in various disease models. -
COX/5-LOX Inhibitor
Phenethyl ferulate is a potent inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), displaying IC50 values of 4.35 μM and 5.75 μM, respectively. This compound exhibits significant anti-inflammatory properties, making it a valuable tool for research into inflammation-related pathways. Its ability to modulate these key enzymes positions it as a promising candidate for studies focused on inflammatory diseases and therapeutic interventions. -
COX Inhibitor
4-Methylamino antipyrine is a COX inhibitor derived from the active metabolite of Metamizole, a pyrazolone non-steroidal anti-inflammatory drug (NSAID). It exhibits analgesic and antipyretic activities, making it beneficial for alleviating pain and reducing fever. Although its anti-inflammatory properties are relatively weak, 4-Methylamino antipyrine serves as a valuable tool in pharmacological studies involving pain management and inflammatory responses. -
COX-2/iNOS Inhibitor
α-Chaconine is an inhibitor of COX-2 and iNOS, which demonstrates significant anti-inflammatory activity. It effectively reduces the transcriptional expression of COX-2, IL-1β, IL-6, and TNF-α. Additionally, α-Chaconine suppresses LPS-induced expression of iNOS and COX-2 at both the protein and mRNA levels, along with their promoter activities in RAW 264.7 macrophages. This makes α-Chaconine a valuable reagent for studies focused on inflammation and related signaling pathways. -
COX Inhibitor
Sphondin is a cyclooxygenase (COX) inhibitor that effectively reduces the levels of COX-2 protein and prostaglandin E2 (PGE2) release in A549 cells stimulated by IL-1β. This compound's anti-inflammatory properties make it a valuable tool for research into COX-related pathways and the modulation of inflammatory responses in various cellular models. Sphondin can facilitate investigations into therapeutic strategies for inflammatory diseases. -
5-LOX/COX Inhibitor
FPL 62064 is a potent dual inhibitor of 5-lipoxygenase (5-LOX) and cyclooxygenase (COX), exhibiting IC50 values of 3.5 μM and 3.1 μM, respectively, in RBL-1 cells. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and related diseases. Its dual inhibition of leukotriene and prostaglandin synthesis positions FPL 62064 as a pertinent reagent for studies focusing on inflammation and related therapeutic interventions. -
sPLA2/COX-2 Inhibitor
Alminoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that functions as an inhibitor of secretory phospholipase A2 (sPLA2) and cyclooxygenase-2 (COX-2). This compound exhibits potent anti-inflammatory activity, making it useful in research focused on inflammation and pain modulation. Its dual mechanism of action presents opportunities for investigating pathways involved in inflammatory diseases and related therapeutic interventions. -
COX Inhibitor
Pelubiprofen is an orally active anti-inflammatory agent that inhibits cyclooxygenase (COX) enzyme activity, displaying IC50 values of 10.66 μM for COX-1 and 2.88 μM for COX-2. It demonstrates notable anti-inflammatory and analgesic properties, making it valuable for research in pain management and inflammation pathways. Pelubiprofen can be utilized in studies examining the roles of COX enzymes in various biological processes and diseases. -
COX Inhibitor
Ketorolac-d5 is a deuterated form of Ketorolac, a non-steroidal anti-inflammatory drug that functions as a nonselective inhibitor of cyclooxygenase (COX). It displays inhibitory potency with IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This compound is widely utilized in pharmacological studies to investigate the biochemical pathways of pain and inflammation, as well as in drug metabolism and pharmacokinetic research. -
COX-2 Inhibitor
EXP3179 is a selective cyclooxygenase-2 (COX-2) inhibitor, notably an intermediate aldehyde metabolite of Losartan. It effectively reduces the expression of COX-2 in endothelial cells, leading to significant anti-inflammatory effects. This compound is useful in research applications focused on inflammation and related signaling pathways. -
COX inhibitor
Meclofenamate Sodium is a dual COX-1/COX-2 inhibitor with IC50 of 40 nM and 50 nM. -
CXCR4 Inhibitor
MSX-122 is an orally bioavailable inhibitor of CXCR4 (IC50 = ~10 nM) with potential antineoplastic and antiviral activities. CXCR4 inhibitor MSX-122 binds to the chemokine receptor CXCR4, preventing the binding of stromal derived factor-1 (SDF-1) to the CXCR4 receptor and receptor activation, which may result in decreased tumor cell proliferation and migration. -
NOS inhibitor
L-NIO dihydrochloride is a potent, non-selective and NADPH-dependent nitric oxide synthase (NOS) inhibitor. -
COX-1 and COX-2 inhibitor
Naproxen etemesil is a lipophilic, non-acidic, inactive prodrug of naproxen that is hydrolysed to pharmacologically active Naproxen once absorbed. Naproxen is a COX-1 and COX-2 inhibitor with IC50s of 8.72 and 5.15 μM, respectively in cell assay. -
COX-2 inhibitor
Bromfenac sodium is a topically selective cyclooxygenase (COX)-2 inhibitor -
COX inhibitor
Flufenamic acid is a nonsteroidal anti-inflammatory drug (NSAID). Inhibits calcium-activated chloride channels (CaCCs). Also increases currents through TRPC6 channels and inhibits currents through TRPC3 and TRPC7 channels. -
COX-2 inhibitor
Valdecoxib, also known as SC-65872, is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, and painful menstruation and menstrual symptoms. It is a selective cyclooxygenase-2 inhibitor. -
IL-1 inhibitor
IX 207-887 is a novel antiarthritic agent which inhibits the release of interleukin-1 (IL-1). -
GPR3 agonist/NOS/ NADPH oxidases inhibitor
Diphenyleneiodonium chloride has been shown to be a potent irreversible inhibitor of NOS2 (iNOS) from macrophages and NOS3 (eNOS) from endothelial cells. -
HIV Entry Inhibitor
BMS-806, also known as BMS-378806 , is a type of medicine called an entry inhibitor. Entry inhibitors work by blocking HIV from entering human cells. BMS-378806 (BMS-806) is a small molecule that blocks the binding of host-cell CD4 with viral gp120 protein and therefore inhibits the first steps of HIV-1 infection. -
COX-2 inhibitor
Iguratimod(T 614) is one of a series of 4H-1-benzopyran-4-ones which has potent anti-inflammatory, analgesic and antipyretic activity. Iguratimod(T 614) is a selective inhibitor of cyclo-oxygenase-2 (COX-2), and inhibits the production of interleukin-1 (IL-1), IL-6, IL-8 and tumour necrosis factor.
